MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Beispiel MedicationRequest: Trastuzumab deruxtecan

German

Profile: MII PR MTB Therapieempfehlung Systemische Therapie version: 2027.0.0-ballot.1

MII EX MTB Empfehlung Priorität: 3

MII EX MTB Empfehlung Evidenzgraduierung: m1B

MII EX MTB Empfehlung Publikation: http://www.ncbi.nlm.nih.gov/pubmed/35665782

MII EX MTB Empfehlung Publikation: http://www.ncbi.nlm.nih.gov/pubmed/37870536

MII EX MTB Empfehlung Publikation: http://doi.org/10.1200/JCO.2023.41.17_suppl.LBA3000

status: Draft

intent: Proposal

medication: Trastuzumab deruxtecan

subject: Kim Musterperson (no stated gender), DoB: 1956-03-14

authoredOn: 2023-03-28

reasonReference: Condition Bösartige Neubildung: Peritoneum, nicht näher bezeichnet